Search Results
Your search for where matches 5550 pages
Showing 4751 - 4800ASTRO Names Three Radiation Oncologists as Recipients of Society’s 2014 Gold Medal
The American Society for Radiation Oncology (ASTRO) has announced the names of three recipients of the Society’s highest honor, the ASTRO Gold Medal. Mary K. Gospodarowicz, MD, FASTRO, Leonard L. Gunderson, MD, MS, FASTRO, and Nancy J. Tarbell, MD, FASTRO, will receive the ASTRO Gold Medal...
'Physician Education Is Key' to Continued Advances in Geriatric Oncology
Several times during his lecture at the 2014 ASCO Annual Meeting, Stuart M. Lichtman, MD, FACP, FASCO, the recipient of the B.J. Kennedy Award for Scientific Excellence in Geriatric Oncology, emphasized, “Physician education is the key” to continued advances in geriatric oncology. He specified that ...
ASCO Convenes Think Tank to Tackle Disparities in Cancer Care
Despite advances in cancer screening and in more effective therapies to treat the disease, which have led to improved outcomes and increased survival rates for millions of people with cancer, not every American is reaping the benefits of these advances. Disparities in health-care access, quality of ...
Patricia M. LoRusso, DO, to Join Yale Cancer Center
Patricia M. LoRusso, DO, a leading expert on drug development through clinical trials, will join Yale Cancer Center in August as a Professor of Medicine and Associate Director of Innovative Medicine at Yale Cancer Center in New Haven, Connecticut. Dr. LoRusso brings more than 25 years of expertise...
Importance of Using Multiplex Testing for Oncogenic Drivers to Select Targeted Drugs in Lung Cancer
Lung cancer is the leading cause of cancer death in the world as well as in the United States, where it is the leading cancer killer in both men and women. The majority of lung cancer patients present with metastatic (stage IV) disease that cannot be cured with current therapies. Standard cytotoxic ...
Yanyan Lou, MD, PhD, Receives Inaugural 2014 Young Investigator Award Supported by the Women Who Conquer Cancer Campaign
Yanyan Lou, MD, PhD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, is the recipient of the very first 2014 Conquer Cancer Foundation of ASCO Young Investigator Award (YIA), generously supported by the Women Who Conquer Cancer. After receiving her medical degree...
ASCO Guideline for Management of Brain Metastases From HER2-Positive Breast Cancer: An Important Framework
Brain metastases are a devastating complication of cancer, and occur in up to 50% of patients with advanced human epidermal growth factor 2 (HER2)-positive breast cancer. Management of brain metastases requires individualized coordination between the traditional treatment modalities for...
James R. Downing, MD, Named CEO of St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital has announced the appointment of James R. Downing, MD, as its new Chief Executive Officer, effective July 15, 2014. Dr. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital. Dr. Downing’s...
Navigating Cancer in the Era of Personalized Medicine: Rev 2014 Explores Emerging Issues, Ideas for Action
Diagnosed with stage IV non–small cell lung cancer in 2011, Stephen Wright turned to patient support groups where he learned about the anaplastic lymphoma kinase (ALK) mutation and a new drug that targeted it, crizotinib (Xalkori). He asked—then insisted—that he be tested for the mutation. He found ...
Ipilimumab Reduces Recurrences as Adjuvant Treatment of Melanoma
Ipilimumab (Yervoy) has transformed the treatment of metastatic melanoma, producing long-term responses in about 20% of patients. A phase III study has now evaluated its impact in the adjuvant setting, and the results are a bit less striking. Primary Endpoint The European Organisation for Research...
IOM Workshop Explores Growing Problems in Patient Access to Cancer Drugs
Cancer patients’ out-of-pocket costs are rising dramatically, and insurance premiums, cost sharing, and ancillary expenses can be devastating. Many people go bankrupt as a result of the high costs of health care. Drugs are among the most serious economic culprits. They grow more expensive every...
International Leader in Urology, Professor John Fitzpatrick, Dies
His life was gentle, and the elements So mixed in him that Nature might stand up And say to all the world, “This was a man!” —William Shakespeare I have too many positive memories of John to regale you with here,” said Roger Kirby, MD, in a tribute to his close friend and colleague, John Michael...
Avoiding Antioxidant-Drug Interactions During Cancer Treatment
Many potential drug-nutrient interactions can affect cancer treatment. It is important to consider these interactions given the significant use of supplements and other self-treatment options during cancer care. Antioxidants account for a large portion of the $32 billion in supplement industry...
From Ireland to America and Back, Patrick G. Johnston, MD, PhD, Thrives on Bringing Research Findings to Clinical Practice
Patrick G. Johnston, MD, PhD, FMedSci, Professor of Oncology and President and Vice-Chancellor of Queen’s University Belfast, grew up in Derry, a city in Northern Ireland. Derry is distinct in being Ireland’s only remaining fully intact walled city, considered one of the finest examples of a walled ...
The Road to Progress in Lung Cancer Treatment
Despite promising new agents and therapeutic approaches, 5-year lung cancer survival rates have lagged far behind those of most other malignancies. To shed light on some of the important issues facing lung cancer experts, The ASCO Post recently spoke with internationally recognized lung cancer...
ASPHO Abstracts Cover Broad Range of Topics
More than 400 abstracts—a record—were submitted for the 27th Annual Meeting of the American Society of Pediatric Hematology/Oncology in Chicago. Here is a small sampling of those studies, with comments from the abstract authors. Token Economy to Improve Compliance BMT Bucks form the basis of a...
FDA Grants Breakthrough Therapy Designation to Investigational Chimeric Antigen Receptor Therapy for Relapsed/Refractory ALL
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). The Breakthrough Therapy filing...
Impressive Delay in Thyroid Cancer Progression Achieved With Lenvatinib
The investigational tyrosine kinase inhibitor lenvatinib reduced disease progression by 79%, as compared to placebo, in patients with metastatic differentiated thyroid cancer that is refractory to radioactive iodine in the phase III SELECT trial. These findings were presented at the 2014 ASCO...
Expert Point of View: Axel Hauschild, MD
Axel Hauschild, MD, Professor of Dermatology at the University Hospital Schleswig-Holstein, Campus Kiel, in Germany, discussed the evolving utility of intralesional approaches to melanoma in the ASCO Poster Highlights session. In general, he maintained that the overall and complete response rates...
Stakeholders Are Uniting Around Value in Cancer Care
Judging from its visibility at the 2014 ASCO Annual Meeting, the concept of “value” in cancer care has reached critical mass. “ASCO is leading this difficult discussion on value in cancer care. This had to happen,” said Clifford A. Hudis, MD, FACP, Immediate Past President of ASCO and Chief of the ...
Take-Home Messages From ASCO's Immediate Past President
The ASCO Post recently spoke with ASCO Immediate Past President Clifford A. Hudis, MD, FACP, about his term as ASCO President. Dr. Hudis discussed his thoughts on ASCO today and shared his perspective on a number of important issues in oncology, including value in cancer care, big data, and more....
Expert Point of View: Howard A. Fine, MD and Martin J. van den Bent, MD
Session moderator Howard A. Fine, MD, the Anne Murnick Cogan and David H. Cogan Professor of Oncology and Director of the Brain Tumor Center at New York University Cancer Institute, shared his enthusiasm over the findings of the RTOG 9802 study. “I don’t know of any other tumor type where the...
What Do Humans and Laboratory Rats Have in Common?
The requirements for sound evidence of a drug’s therapeutic benefit have translated laboratory experience to human testing. In the laboratory, experimental animals give their lives to lethal testing of drugs and scientific analysis. LD50, the terminology denoting an anticipated 50% death rate of...
New Clinical Study Aims to Investigate the Genomics of Young Lung Cancer
The Addario Lung Cancer Medical Institute (ALCMI) recently launched a new study, the Genomics of Young Lung Cancer, to understand why lung cancer occurs in young adults, who quite often are athletic, never smokers and do not exhibit any of the known lung cancer genetic mutations. ALCMI, a...
Cancer Survivor and Patient Advocate Michael S. Katz, MBA, Has Helped Alter the Standard of Care for Myeloma Survivors
Michael S. Katz, MBA, has lived longer than any of his doctors thought he would. A two-time cancer survivor, Mr. Katz was diagnosed, first with multiple myeloma in 1990 and then with colorectal cancer in 2008, and has spent the past 2 decades tirelessly advocating for patients with cancer. The...
V. Craig Jordan, PhD, to Join MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center has announced that V. Craig Jordan, PhD, will join the institution in October 2014 as a Professor in Breast Medical Oncology and Molecular and Cellular Oncology. Dr. Jordan will focus on the new biology of estrogen-induced cell death with the goal...
How Technology Is Helping Bring Health Care to Patients
The term “telemedicine,” which is sometimes used interchangeably with “telehealth” and “m-health” (for mobile health) and is now collectively called “connected health,” involves the use of information and communications technology to connect patients with their providers through a variety of...
Michael Douglas Shares His Experience With Stage IV Oropharyngeal Cancer
Academy Award winning actor and producer Michael Douglas was the guest of honor at the opening day of the International Federation of Head and Neck Oncologic Societies (IFHNOS) 5th World Congress on July 27 in New York (see page 22 for more on the World Congress). He came not to plug the release of ...
Book Excerpt: Family
I've witnessed incredible courage and zest for life among so many patients from so many walks of life—individuals committed to helping others in spite of their own adversity. Forty years ago, when survival for patients with multiple myeloma was a matter of months, I knew that every person I sat...
Oncologists Tell Inspiring Stories of What It’s Like to Treat Cancer in The Big Casino
Title: The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful StoriesEditors: Stan Winokur, MD, and Vincent CoppolaPublishing Platform: CreateSpacePublication date: May 2014Price: $9.99; Paperback, 160 pages In May, Stan Winokur, MD, and co-editor Vincent Coppola, published The...
Using Patient-Reported Outcome Measures in Palliative Care Clinical Practice
Incorporating patient-reported outcomes into the palliative care clinical setting can improve patients’ symptom management, quality of life, and overall communication with their oncologists, according to Ethan Basch, MD. Dr. Basch is Director of the Cancer Outcomes Research Program and Associate...
Discussing Sexual Health Issues With Female Cancer Survivors
Advances in cancer treatment have led to increasing numbers of long-term survivors, bringing greater attention to the needs of this growing population. Female cancer patients often experience difficult adjustments related to sexual health and intimacy. To better understand the complexity of this...
Pioneering Medical Oncologist Remembers a Time Before the Subspecialty Was Created
While the first written record of cancer dates back to ancient Egypt, the history of modern oncology is fairly short, dating back only slightly more than half a century. Clinical trials in the early days of the National Cancer Institute (NCI) and the emerging cooperative groups were led by a...
Holy Name Medical Center of New Jersey Welcomes Sharyn N. Lewin, MD, FACS, and Phyllis Tarallo, DNP, DCC
Holy Name Medical Center (HNMC) welcomes gynecologic oncologist, hereditary cancer risk, and women’s health specialists Sharyn N. Lewin, MD, FACS, and Phyllis A. Tarallo, DNP, DCC, both of whom will be members of the Holy Name Physician Network. Holy Name Medical Center is a fully accredited,...
Prominent Immunotherapy Researcher Sees Success Beyond the Challenges
Activating the immune system for therapeutic benefit in cancer patients has long been a goal in the scientific community. After decades of disappointment, this intriguing approach has come to the forefront of cancer research, showing promising results in several malignancies. To keep abreast of...
Getting Results: How Oncologists and Pathologists Can Work Together to Facilitate Molecular Testing
Advances in molecular testing mean that highly specific information can be detailed about the molecular characteristics of a patient’s tumor, as well as indications of potential responsiveness to targeted therapy. But getting those detailed results from the pathologists can be a challenge to many...
FDA Approval of Ceritinib for the Treatment of ALK-Positive Non–Small Cell Lung Cancer
INSIDE THE BLACK BOX is an occasional column providing insight into the U.S. Food and Drug Administration (FDA) and its policies and procedures. In this installment, FDA oncologists Sean Khozin, MD, MPH, and Dikran Kazandjian, MD, discuss anaplastic lymphoma kinase (ALK)-positive non–small cell...
More Collaboration Needed Between Oncologists and Primary Care Physicians
One of the most important cancer survivorship issues is the transition from oncologist to the primary care setting. With a growing population of cancer survivors, patients need to feel secure about their primary care provider having the tools to address their special needs. To shed light on this...
Fred Hutchinson Cancer Research Center Researcher Veena Shankaran, MD, to Receive ‘40 Under 40’ Award
The Puget Sound Business Journal (PSBJ) has recognized Veena Shankaran, MD, a Medical Oncologist and Health Economist at Fred Hutchinson Cancer Research Center, as one of 40 individuals under age 40 who have demonstrated extraordinary leadership within their field. Dr. Shankaran will accept the...
The Evolving Role of Surgery in Germ Cell Tumors
Over the past several decades, the role of postchemotherapy surgery for advanced testicular cancer has evolved with regard to patient selection, surgical planning, lymph node dissection, and surgical technique. To add clarity to this complex clinical setting, The ASCO Post recently spoke with...
Supportive Care in Pediatric Patients With Cancer: Recent Developments in Treating Febrile Neutropenia
Recent developments in supportive care for children with cancer can be broken down into three categories: doing the simple things well, applying evidence-based medicine to daily practice, and extending the benefits to everyone, according to Scott C. Howard, MD, of St. Jude Children’s Research...
Rational Strategies Are Advancing Combination Lymphoma Therapies
Rational strategies informed by knowledge of a drug’s molecular mechanisms are helping to bring new combinations of lymphoma therapies to the clinic, according to Anas Younes, MD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York. The Challenge of Too Many Drugs...
Precision Medicine: Precisely Where Are We Really?
Having attended ASCO Annual Meetings for almost 40 years, I believe that this year’s 50th anniversary celebration was one of the best ever. In many of the presentations and discussions, I experienced a sense of reality about the true state of cancer management that in previous years has sometimes...
New Research Presented in Wilms Tumor, Pediatric Sarcoma, Head and Neck Cancer, and Non–Small Cell Lung Cancer
In the past few months, numerous presentations from this year’s ASCO Annual Meeting have been covered in depth in the pages of The ASCO Post and online at ASCOPost.com. The brief summaries below capture additional important highlights that have not been covered thus far. We hope you will find them...
Expert Point of View: Federico Cappuzzo, MD
Federico Cappuzzo, MD, Director of the Medical Oncology Department at Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy, pointed out that the abstracts presented by Spigel et al and Camidge et al at the ASCO Annual Meeting explored the same target but with different results. The first...
Mixed Results for Targeting MET in Non–Small Cell Lung Cancer
Two different abstracts explored the potential for MET as a therapeutic target in patients with metastatic non–small cell lung cancer (NSCLC), with different results. A phase III study found that onartuzumab, an antibody that targets the MET receptor, combined with erlotinib (Tarceva) was not as...
Who Will Care for Patients With Cancer?
The workforce numbers show a disturbing trend. According to a recent study by ASCO, by 2025, overall demand for oncology services is projected to grow by 40%, but physician supply is predicted to increase by only 25%, generating a shortage of 2,258 oncologists providing full-time equivalent...
Does the United States Have the Best Health-Care System in the World?
Many concerns were raised and dire speculations predicted during the further implementation of the Affordable Care Act this year. So far, the trickling news is good: An estimated total of 20 million people gained coverage under the new law as of May 1,1 about 6 million enrolled in the law’s...
Pioneer in Fight Against Tobacco, Emanuel Farber, MD, PhD, Dies at 85
On December 11, 1969, a soft-spoken pathologist wearing outsized spectacles answered a long and complex series of questions by the legal team representing Liggett & Myers Tobacco Company, the maker of Chesterfield cigarettes. The tobacco lawyers contended that one Leslie Thayer—a lifelong...
Jesse L. Steinfeld, MD, Past Surgeon General, ASCO President, Dies at 87
The 1964 Surgeon General’s Report on Smoking and Health started a culture change in the way Americans viewed tobacco and their health, and has saved countless million of lives. But the 1964 Report remained scientifically ambiguous on certain vital issues, such as the effect smoking had on the...
